Artificial intelligence is reshaping biotechnology, diagnostics and drug discovery. At the same time, Europe is competing globally for capital, talent and technological leadership. Bio:cap aims to strengthen this ecosystem by connecting investors, startups, researchers and policymakers in a new international investival in Berlin.
AI meets biotech: Europe’s new investival
Sponsored PublicationsArtificial intelligence is reshaping biotechnology, diagnostics and drug discovery. At the same time, Europe is competing globally for capital, talent and technological leadership. Bio:cap aims to strengthen this ecosystem by connecting investors, startups, researchers and policymakers in a new international investival in Berlin.
EU backs Novo Nordisk’s oral Wegovy for weight management
Latest NewsNovo Nordisk has moved a step closer to bringing an oral version of Wegovy to the European obesity market, after the Committee for Medicinal Products for Human Use (CHMP) recommended approval of once-daily oral semaglutide 25 mg for weight management.
OSE’s Tedopi-Keytruda combo clears Phase II ovarian cancer hurdle
Latest NewsFrench biotech OSE Immunotherapeutics has reported positive topline Phase II data for its cancer vaccine Tedopi in recurrent ovarian cancer, but the clinical signal is most clearly seen in combination with MSD’s anti-PD-1 antibody Keytruda.
Days after J&J update, Nanobiotix pauses trading amid €75M stock offering
Latest NewsNanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect.
Infex reports Phase IIa win for anti-Pseudomonas antibody
Latest NewsA new monoclonal antibody approach could add an infection-directed option to the changing treatment landscape for non-cystic fibrosis bronchiectasis.
SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug
Latest NewsSERB Pharmaceuticals has agreed to pay Hansa Biopharma €110 million upfront for European rights to a conditionally approved kidney transplant drug.
New CCO starts in June
AppointmentsMarc Clausse will take up his new role as Chief Commercial Officer at Santhera Pharmaceuticals (SIX: SANN) at the beginning of June. He succeeds Geert Jan van Daal, who is retiring.
Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet
Latest NewsHarbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform.
Co-founder and CEO steps down
AppointmentsDr Andrea Pfeifer, long-serving CEO and co-founder from AC Immune, has decided to retire. AC Immune’s Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.
$55m financing round for NVision
Latest NewsWith $55m in fresh capital, Ulm-based NVision is expanding its quantum technology platform from MRI sensing into quantum computing for drug development. The diagnostics company Abbott is the round’s anchor investor.